Rankings / Cognitive — Nootropics
Solriamfetol (Sunosi)
Cognitive · DNRI / wakefulness-promoting
Tier B+
What this is
Jazz Pharmaceuticals; brand Sunosi. Direct-acting dopamine/norepinephrine reuptake blocker — closer mechanistically to amphetamines than to modafinil. Often used when modafinil/armodafinil insufficient or contraindicated. Notable BP increases at higher doses limit cardiovascular-impaired patients. 2024 OSA-specific Phase 4 data confirmed sustained efficacy.
Mechanism
Selective dopamine and norepinephrine reuptake inhibitor (DNRI) with mild abuse potential; distinct from modafinil's adenosine/orexin pathway; FDA-approved 2019 for excessive daytime sleepiness in narcolepsy and OSA
Dose & route
75-150 mg PO once daily
Citations
- https://pubmed.ncbi.nlm.nih.gov/41233821/
- https://pubmed.ncbi.nlm.nih.gov/30702348/
- https://pubmed.ncbi.nlm.nih.gov/31021471/
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.